Cargando…
Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413692/ https://www.ncbi.nlm.nih.gov/pubmed/34493918 http://dx.doi.org/10.1007/s40274-021-07997-6 |
Ejemplares similares
-
Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021) -
Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
Publicado: (2021) -
Effects on LOS may not justify cost of remdesivir for severe COVID-19
Publicado: (2021) -
Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021) -
Expediting COVID-19 vaccination increases QALYs and saves costs in the USA
Publicado: (2021)